This counterintuitive outcome demonstrated, through both in vitro and in vivo experiments, that a nuanced mechanism where a diminished LRP1 endocytosis is associated with a reduced Aβ deposition in AD, providing intriguing avenues for therapeutic exploration [126]. This evidence concerns the gene LRP1 and Alzheimer disease.